

References — Pariet

1. Product monograph of Pariet (rabeprazole sodium). Janssen-Ortho Inc. Toronto, On. May 31, 2002.
2. Welbanks L, editor. Compendium of Pharmaceuticals and Specialties, 37th Edition. Canadian Pharmacists Association, 2002, Ottawa.
3. Breiter JR, Riff D, Humphries TJ, et al. Rabeprazole is superior to ranitidine in the management of active duodenal ulcer disease Results of a double-blind, randomized North American study. *Am J Gastroenterol* 2000;95(4): 936-42.
4. Caro JJ, Salas M, Ward A. Healing and relapse rates in gastroesophageal reflux disease treated with the ewer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: Evidence from randomized clinical trials. *Clin Therapeut* 2001;23(7):998-1017.
5. Dekkers CPM, Beker JA, Thjodleifsson B, et al. Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study. *Aliment Pharmacol Ther* 1999;13:179-86.
6. Dekkers CPM, Beker JA, Thjodleifsson B, et al. Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer – a European multicentre study. *Aliment Pharmacol Ther* 1998;12:789-95.
7. Edwards SJ, Lind T, Lundell L. Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis. *Aliment Pharmacol Thera* 2001;15:17289-36.
8. Erstad BL. Dyspepsia: Initial evaluation and treatment. *J Am Pharm Assoc* 2002;42:460-
9. Farley A, Wruble LD, Humphries TJ, et al. Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: A double-blind, randomized clinical trial. *Am J Gastroenterol* 2000;95(8):1894-9.
10. Gray J (ed). Therapeutic Choices, 3rd edition. Canadian Pharmacists Association, 2000; Ottawa.
11. Saltiel E, Stein T. Proton pump inhibitors in the treatment of GERD. *US Pharmacist* 2000;25(4) Supplement:3-13.
12. Tierney LM, McPhee SJ, Papadakis MA (eds). Current Medical Diagnosis and Treatment, 39th ed., 2000. Lange Medical Books/McGraw-Hill, Toronto.
13. Galmiche JP, Zerbib F, Ducrotte P, et al. Decreasing oesophageal acid exposure in patients with GERD: a comparison of rabeprazole and omeprazole. *Aliment Pharmacol Ther* 2110;15:1343-50.
14. Holtmann G, Bytzer P, Metz M, et al. A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease. *Aliment Pharmacol Ther* 2002;16:479-85.
15. Lanza F, Dev Bardhan K, Perdomo C, et al. Efficacy of rabeprazole once daily for acid-related disorders. *Dig Dis Sci* 2001;46(3):587-96.
16. New Pariet (rabeprazole sodium) Tablets Now Approved in Canada! [press release]. Janssen-Ortho Inc. July 29, 2002.
17. Thjodleifsson B, Beker JA, Dekkers C, et al. Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease. *Digest Dis Sci* 2000;45(5):845-53.